Eif4G1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Eukaryotic translation initiation factor 4 gamma 1 (eIF4G1) is a massive 220 kDa scaffolding protein that plays a central role in cap-dependent mRNA translation. As part of the eIF4F complex (eIF4E, eIF4A, eIF4G), eIF4G1 coordinates the assembly of the translation initiation machinery and regulates protein synthesis. Mutations in EIF4G1 have been linked to Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), establishing eIF4G1 as a critical nexus between translational dysregulation and neurodegeneration [1][2].
| eIF4G1 | |
|---|---|
| Protein Name | Eukaryotic translation initiation factor 4 gamma 1 |
| Gene | EIF4G1 |
| UniProt ID | Q09470 |
| PDB IDs | 1LVZ, 1Q0N |
| Molecular Weight | 220 kDa |
| Subcellular Localization | Cytoplasm, stress granules, P-bodies |
| Protein Family | eIF4G family |
| Isoforms | Multiple isoforms (eIF4G1-4) |
eIF4G1 is a 1859-amino acid protein containing multiple functional domains:
MIF4G domain (residues 650-800): The middle domain of eIF4G binds eIF4A (DEAD-box helicase) and is essential for helicase activity. This domain also interacts with other translation factors [3].
HEAT-1 and HEAT-2 domains: These helical repeat domains provide protein-protein interaction surfaces for binding eIF4E, eIF3, and other factors [4].
PABP-binding site (C-terminal): The poly(A)-binding protein (PABP) interaction site enables circularization of mRNA, enhancing translation efficiency and mRNA stability [5].
eIF4E-binding site: Competes with 4E-BP (eIF4E-binding protein) for eIF4E binding, regulating cap-dependent translation [6].
WW domain: A proline-rich region involved in protein-protein interactions.
RNA-binding region: The C-terminal portion contains RNA-binding activity that contributes to mRNA recruitment [7].
eIF4G1 is a central scaffold protein in the translation initiation machinery:
eIF4G1 forms the eIF4F complex with eIF4E (cap-binding protein) and eIF4A (helicase). This complex binds the 5' m7G cap structure of mRNA and recruits the 43S preinitiation complex. eIF4G1 serves as the scaffold, simultaneously interacting with eIF4E, eIF4A, eIF3, and PABP [8].
eIF4G1 activity is regulated by:
Under stress conditions (oxidative stress, heat shock, viral infection), eIF4G1 localizes to stress granules - cytoplasmic mRNP aggregates that stall translation initiation. This is part of the cellular stress response [10].
In neurons, local translation at synapses is crucial for synaptic plasticity. eIF4G1-mediated translation regulation controls expression of synaptic proteins underlying learning and memory [11].
EIF4G1 was identified as a PD risk gene through genetic studies:
PD-associated mutations: Several EIF4G1 variants (A502V, R1205H) have been associated with increased PD risk in various populations. These mutations may affect protein function or expression [12].
Dysregulated translation: PD-related proteins including LRRK2, parkin, and alpha-synuclein affect translational control. eIF4G1 dysfunction may contribute to impaired protein homeostasis [13].
Stress granule accumulation: eIF4G1-positive stress granules accumulate in PD models and may contribute to alpha-synuclein aggregation [14].
Therapeutic implications: Modulating eIF4G1 activity or stress granule dynamics is being explored as a therapeutic strategy [15].
ALS is characterized by progressive motor neuron loss:
Genetic association: EIF4G1 mutations have been reported in some ALS cases, though less commonly than in PD [16].
Stress granule dynamics: ALS-associated stress granule dysregulation involves eIF4G1. Mutations in FUS, TDP-43, and C9orf72 affect stress granule biology [17].
Translation inhibition: Strategies to modulate eIF4G1 cleavage or stress granule formation are being investigated [18].
| Approach | Status | Description |
|---|---|---|
| mTOR inhibitors | Approved | Rapamycin, everolimus to modulate translation |
| 4E-BP activators | Preclinical | Promote eIF4F complex assembly |
| Stress granule modulators | Research | Prevent pathological aggregation |
| Gene therapy | Preclinical | AAV-mediated eIF4G1 modulation |
Eif4G1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Eif4G1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Chartier-Harlin MC, et al. (2011). EIF4G1 mutations in Parkinson's disease. Lancet 377: 153-154.
Smith LM, et al. (2015). EIF4G1 in neurodegeneration. Neurobiol Aging 36: 2905.e1-2905.e10.
Baird SD, et al. (2006). eIF4G structure and function. Biochem Soc Trans 34: 715-720.
Marintchev A, et al. (2009). eIF4G HEAT domains. RNA 15: 1219-1230.
Kahvejian A, et al. (2001). eIF4G and PABP interaction. EMBO J 20: 2575-2586.
Gingras AC, et al. (1999). eIF4E and 4E-BP. Genes Dev 13: 1422-1437.
Hernandez G, et al. (2015). eIF4G1 RNA binding. Biochim Biophys Acta 1849: 1013-1024.
Sonenberg N, Hinnebusch AG (2009). eIF4F complex assembly. Cell 136: 731-745.
Walsh D, Mohr I (2011). Viral manipulation of eIF4G1. Nat Rev Microbiol 9: 860-870.
Anderson P, Kedersha N (2009). Stress granules. Trends Cell Biol 19: 175-185.
Klann E, Dever TE (2004). Synaptic translation. Nat Rev Neurosci 5: 931-942.
Nuytemans K, et al. (2014). EIF4G1 variants in PD. Mov Disord 29: 1573-1580.
Jiang J, et al. (2019). eIF4G1 and PD pathogenesis. J Neurosci 39: 5538-5550.
Molliex A, et al. (2015). Phase separation and stress granules. Cell 163: 123-133.
Zhang K, et al. (2019). Stress granules in neurodegeneration. Nat Rev Neurol 15: 671-682.
Boeynaems S, et al. (2016). ALS and stress granules. Nat Rev Neurosci 17: 195-207.
Wang C, et al. (2021). Targeting stress granules in ALS. Trends Neurosci 44: 81-92.
Ma T, et al. (2010). mTOR and eIF4G1 in AD. J Neurosci 30: 15068-15078.